Key points from article :
Amber Bio has oversubscribed $26 million seed financing round as it builds editing platforms to previously undruggable diseases.
It is developing a new RNA editing platform that can “correct genetic mutations in a safe and reversible way."
Funding to advance development of its platform, allowing a single drug to treat diseases with high allelic diversity.
This would benefit patients who suffer from diseases that arise from diverse mutations.
It is developing its own genetic medicine programs in-house.
“Current technologies rely on creating solutions on a per-mutation basis, which is not scalable across a highly diverse patient population in the US and globally,” - Basem Al-Shayeb, Amber's CTO.
“We’re creating an entirely new ability to rewrite RNA & restore human health in many disease settings,” - Jacob Borrajo, Amber Bio's CEO.
“Our approach leverages novel, iteratively engineered Cas-based systems for durable RNA editing, creating significant advantages over editing DNA, which can lead to permanent, off-target mutations,” said Borrajo.
